



January 18, 2024

---

**Subject:** Introducing GLASSIA® in Canada

---

Dear Healthcare Professional,

Takeda Canada Inc. is pleased to announce the introduction of GLASSIA® (alpha-1 proteinase inhibitor [human] injection) indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha1-PI, also known as alpha1-antitrypsin deficiency (AATD). GLASSIA® increases antigenic and functional (anti-neutrophil elastase capacity, ANEC) serum levels.

The recommended dose of GLASSIA® is 60 mg/kg body weight of GLASSIA® once weekly by intravenous infusion. GLASSIA® is a solution/2% A1-PI/ 0.02M Monobasic Sodium Phosphate Dihydrate/ 0.7 % Sodium Chloride/ 50 mL Water for Injection.

GLASSIA® will be available through Canadian Blood Services (CBS) starting February 29<sup>th</sup> 2024.

**You can obtain additional information on GLASSIA® by:**

consulting the GLASSIA® Product Monograph at <https://www.takeda.com/en-ca/glassiapm> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use; or contacting Takeda Medical Information at +1800-268-2772 or [medinfoCA@takeda.com](mailto:medinfoCA@takeda.com).

Sincerely,

## Ascher Essebag

Vice President, Rare Disease

22 Adelaide Street West, Suite 3800

Toronto, ON M5H 4E3, Canada

Telephone: +1.647.798.2200 or 1.866.397.4473

<https://www.takeda.com/en-ca>

Reference: 1. GLASSIA® Product Monograph, Takeda Canada Inc. November 12, 2021

GLASSIA is a registered trademark used under license from Kamada Ltd.

TAKEDA and  are registered trademarks of Takeda Pharmaceutical Company Limited, used under license.